{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:14:24Z","timestamp":1788509664269,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.xphs.2026.104346","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T06:50:55Z","timestamp":1779864655000},"page":"104346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Delay differential equation modeling of CAR-T cellular kinetics: Application to BCMA-targeted (Ide-cel, Orva-cel) and CD19-targeted (Lisocel) therapies"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5428-9418","authenticated-orcid":false,"given":"Yiming","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.xphs.2026.104346_bib0001","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.xphs.2026.104346_bib0002","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2024.13171","article-title":"CAR\u2011T cell therapy: a breakthrough in traditional cancer treatment strategies (Review)","volume":"29","author":"Sun","year":"2024","journal-title":"Mol Med Rep"},{"issue":"5","key":"10.1016\/j.xphs.2026.104346_bib0003","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/cpt.2509","article-title":"Clinical pharmacology perspectives for adoptive cell therapies in oncology","volume":"112","author":"Huang","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.xphs.2026.104346_bib0004","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.xphs.2026.104346_bib0005","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xphs.2026.104346_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114421","article-title":"Cellular kinetics: a clinical and computational review of CAR-T cell pharmacology","volume":"188","author":"Qi","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"10.1016\/j.xphs.2026.104346_bib0007","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s40262-025-01531-2","article-title":"Population cellular kinetics of Idecabtagene Vicleucel in patients with triple-class-exposed relapsed\/refractory multiple myeloma","volume":"64","author":"Wu","year":"2025","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.xphs.2026.104346_bib0008","article-title":"Integrative population pharmacokinetic modeling of two BCMA-targeted and one CD19-targeted CAR-T therapies using full bayesian inference with a student's t-based M3 censoring approach for robust handling of outliers and BLQ data","volume":"114","author":"Cheng","year":"2025","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2026.104346_bib0009","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40262-021-01039-5","article-title":"Population cellular kinetics of Lisocabtagene Maraleucel, an autologous CD19-directed chimeric antigen receptor T-cell product, in patients with relapsed\/refractory large B-cell lymphoma","volume":"60","author":"Ogasawara","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.xphs.2026.104346_bib0010","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1158\/1078-0432.CCR-24-2753","article-title":"Population pharmacokinetics of Orvacabtagene Autoleucel, an autologous BCMA-directed chimeric antigen receptor T-cell product, in patients with relapsed\/refractory multiple myeloma","volume":"31","author":"Hu","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.xphs.2026.104346_bib0011","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/psp4.12388","article-title":"Tisagenlecleucel model-based cellular kinetic analysis of chimeric antigen receptor-T cells","volume":"8","author":"Stein","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.xphs.2026.104346_bib0012","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jtbi.2012.12.025","article-title":"Quantifying T lymphocyte turnover","volume":"327","author":"De Boer","year":"2013","journal-title":"J Theor Biol"},{"issue":"212","key":"10.1016\/j.xphs.2026.104346_bib0013","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2023.0369","article-title":"Understanding the impact of numerical solvers on inference for differential equation models","volume":"21","author":"Creswell","year":"2024","journal-title":"J R Soc Interface"},{"issue":"11","key":"10.1016\/j.xphs.2026.104346_bib0014","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nri3307","article-title":"Transcriptional control of effector and memory CD8+ T cell differentiation","volume":"12","author":"Kaech","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.xphs.2026.104346_bib0015","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.4049\/jimmunol.1100363","article-title":"Duration of antigen availability influences the expansion and memory differentiation of T cells","volume":"187","author":"Blair","year":"2011","journal-title":"J Immunol"},{"issue":"19","key":"10.1016\/j.xphs.2026.104346_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910828","article-title":"Improving CAR T-cell persistence","volume":"22","author":"Pietrobon","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"16","key":"10.1016\/j.xphs.2026.104346_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16162858","article-title":"Strategies for improving CAR T cell persistence in solid tumors","volume":"16","author":"Wittling","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xphs.2026.104346_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105498","article-title":"Delay differential equations for the description of Irbesartan pharmacokinetics: a population approach to model absorption complexities leading to dual peaks","volume":"153","author":"Karatza","year":"2020","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2026.104346_bib0019","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.3934\/dcdsb.2025073","article-title":"Influence of time delay on the dynamics of a mathematical model of CAR-T cell therapy with logistic tumor growth","volume":"30","author":"Szafra\u0144ska-\u0141\u0229czycka","year":"2025","journal-title":"Discrete and Continuous Dynamical Systems - Series B"},{"issue":"6","key":"10.1016\/j.xphs.2026.104346_bib0020","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10928-021-09770-z","article-title":"Delay differential equations based models in NONMEM","volume":"48","author":"Yan","year":"2021","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"10.1016\/j.xphs.2026.104346_bib0021","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00285-003-0211-0","article-title":"A delay differential equation model for tumor growth","volume":"47","author":"Villasana","year":"2003","journal-title":"J Math Biol"},{"issue":"2","key":"10.1016\/j.xphs.2026.104346_bib0022","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3934\/mbe.2012.9.241","article-title":"Delay equations modeling the effects of phase-specific drugs and immunotherapy on proliferating tumor cells","volume":"9","author":"Barbarossa","year":"2012","journal-title":"Math Biosci Eng"},{"issue":"12","key":"10.1016\/j.xphs.2026.104346_bib0023","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.3934\/mbe.2025113","article-title":"Recent advances in ODEs modeling of tumor-immune responses: a focus on delay effects","volume":"22","author":"Arredondo","year":"2025","journal-title":"Math Biosci Eng"},{"issue":"8","key":"10.1016\/j.xphs.2026.104346_bib0024","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.4049\/jimmunol.171.8.3928","article-title":"Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection","volume":"171","author":"De Boer","year":"2003","journal-title":"J Immunol"},{"issue":"6132","key":"10.1016\/j.xphs.2026.104346_bib0025","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.1235454","article-title":"Disparate individual fates compose robust CD8+ T cell immunity","volume":"340","author":"Buchholz","year":"2013","journal-title":"Science"},{"issue":"7685","key":"10.1016\/j.xphs.2026.104346_bib0026","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature24633","article-title":"Origin and differentiation of human memory CD8 T cells after vaccination","volume":"552","author":"Akondy","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.xphs.2026.104346_bib0027","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.3389\/fimmu.2019.01927","article-title":"From discrete to continuous modeling of lymphocyte development and plasticity in chronic diseases","volume":"10","author":"Enciso","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.xphs.2026.104346_bib0028","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1128\/aem.56.6.1875-1881.1990","article-title":"Modeling of the bacterial growth curve","volume":"56","author":"Zwietering","year":"1990","journal-title":"Appl Environ Microbiol"},{"issue":"3","key":"10.1016\/j.xphs.2026.104346_bib0029","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/ni1040","article-title":"Duration of TCR signaling controls CD4-CD8 lineage differentiation in vivo","volume":"5","author":"Liu","year":"2004","journal-title":"Nat Immunol"},{"issue":"35","key":"10.1016\/j.xphs.2026.104346_bib0030","doi-asserted-by":"crossref","first-page":"E3679","DOI":"10.1073\/pnas.1413726111","article-title":"A sharp T-cell antigen receptor signaling threshold for T-cell proliferation","volume":"111","author":"Au-Yeung","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.xphs.2026.104346_bib0031","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.it.2021.09.004","article-title":"Staggered starts in the race to T cell activation","volume":"42","author":"Richard","year":"2021","journal-title":"Trends Immunol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104346_bib0032","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202254969","article-title":"Time required for commitment to T cell proliferation depends on TCR affinity and cytokine response","volume":"24","author":"Wu","year":"2023","journal-title":"EMBO Rep"},{"key":"10.1016\/j.xphs.2026.104346_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/982978","article-title":"Delay differential model for tumour-immune response with chemoimmunotherapy and optimal control","volume":"2014","author":"Rihan","year":"2014","journal-title":"Comput Math Methods Med"},{"issue":"1","key":"10.1016\/j.xphs.2026.104346_bib0034","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s13662-021-03621-4","article-title":"Mathematical analysis of a cancer model with time-delay in tumor-immune interaction and stimulation processes","volume":"2021","author":"Dehingia","year":"2021","journal-title":"Adv Differ Equ"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2026.104346_bib0035","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0377-0427(00)00468-4","article-title":"Numerical modelling in biosciences using delay differential equations","volume":"125","author":"Bocharov","year":"2000","journal-title":"J Comput Appl Math"},{"issue":"1","key":"10.1016\/j.xphs.2026.104346_bib0036","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3934\/mbe.2015.12.185","article-title":"Virus dynamics model with intracellular delays and immune response","volume":"12","author":"Song","year":"2015","journal-title":"Math Biosci Eng"},{"issue":"4","key":"10.1016\/j.xphs.2026.104346_bib0037","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10928-014-9368-y","article-title":"Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations","volume":"41","author":"Koch","year":"2014","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"7","key":"10.1016\/j.xphs.2026.104346_bib0038","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/psp4.70046","article-title":"Tutorial for modeling delays in biological systems in the NONMEM software","volume":"14","author":"Bauer","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"7","key":"10.1016\/j.xphs.2026.104346_bib0039","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/imcb.12254","article-title":"Chimeric antigen receptor T cell persistence and memory cell formation","volume":"97","author":"McLellan","year":"2019","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104346_bib0040","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","article-title":"Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies","volume":"14","author":"Tao","year":"2024","journal-title":"Blood Cancer J"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T07:34:42Z","timestamp":1788507282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926001954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0022354926001954"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104346","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delay differential equation modeling of CAR-T cellular kinetics: Application to BCMA-targeted (Ide-cel, Orva-cel) and CD19-targeted (Lisocel) therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104346"}}